These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16893083)

  • 41. Role of the complement receptor CR1 in the processing of substrate-bound C3.
    Medof ME; Iida K; Nussenzweig V
    Ann N Y Acad Sci; 1983; 421():299-306. PubMed ID: 6586104
    [No Abstract]   [Full Text] [Related]  

  • 42. [Substances contained in the coelomic fluid of Lumbricus terristris having functions in common with those of some human complement components].
    Laulan A; Lestage J; Châteaureynaud-Duprat P; Fontaine M
    Ann Immunol (Paris); 1983; 134D(2):223-32. PubMed ID: 6559048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Progress on complement protein chemistry and the molecular mechanism of activation. Alternative complement pathway].
    Kinoshita T
    Nihon Rinsho; 1988 Sep; 46(9):1894-8. PubMed ID: 3241383
    [No Abstract]   [Full Text] [Related]  

  • 44. Conversion of the C3 component of complement in mice infected with Trypanosoma cruzi.
    Irulegui I; Chaves J; Ferri RG; de Souza ZW; de Souza HB; Castilho EA
    Rev Inst Med Trop Sao Paulo; 1980; 22(2):62-8. PubMed ID: 6776614
    [No Abstract]   [Full Text] [Related]  

  • 45. Mice transgenic for human CD46 and CD55 are protected from human complement attack.
    Mulder LC; Mora M; Ciccopiedi E; Melli C; Nuti S; Marinucci G; Bruzzone P; Lazzeri M; Lorenzini R; Alfani D
    Transplant Proc; 1995 Feb; 27(1):333-5. PubMed ID: 7533403
    [No Abstract]   [Full Text] [Related]  

  • 46. Third component of trout complement. cDNA cloning and conservation of functional sites.
    Lambris JD; Lao Z; Pang J; Alsenz J
    J Immunol; 1993 Dec; 151(11):6123-34. PubMed ID: 8245455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structures of complement component C3 provide insights into the function and evolution of immunity.
    Janssen BJ; Huizinga EG; Raaijmakers HC; Roos A; Daha MR; Nilsson-Ekdahl K; Nilsson B; Gros P
    Nature; 2005 Sep; 437(7058):505-11. PubMed ID: 16177781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
    Blok VT; Daha MR; Tijsma O; Harris CL; Morgan BP; Fleuren GJ; Gorter A
    J Immunol; 1998 Apr; 160(7):3437-43. PubMed ID: 9531304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs.
    de Cordoba SR; Tortajada A; Harris CL; Morgan BP
    Immunobiology; 2012 Nov; 217(11):1034-46. PubMed ID: 22964229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Active sites in complement component C3 mapped by mutations at indels.
    Ogata RT; Ai R; Low PJ
    J Immunol; 1998 Nov; 161(9):4785-94. PubMed ID: 9794410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Complement and bio-phylaxis].
    Nihon Rinsho; 1990 Jul; 48 Suppl():342-440. PubMed ID: 2214200
    [No Abstract]   [Full Text] [Related]  

  • 52. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases.
    De Vecchi A; Montagnino G; Scalia P; Tarantino A
    Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054
    [No Abstract]   [Full Text] [Related]  

  • 53. [Progress in the knowledge of complement. I. Structure, activation and control of the complement system].
    Lesavre P; Leibowitch J
    Nouv Presse Med; 1979 Jun; 8(29):2385-7. PubMed ID: 493022
    [No Abstract]   [Full Text] [Related]  

  • 54. Inactivation of C3 and C5 prolongs cardiac xenograft survival and decreases leukocyte infiltration in a model of delayed xenograft rejection.
    Johnson EM; Leventhal J; Dalmasso AP; Goswitz J; Simone P; Chen S; Matas AJ
    Transplant Proc; 1996 Apr; 28(2):603. PubMed ID: 8623296
    [No Abstract]   [Full Text] [Related]  

  • 55. Storage of the complement components C4, C3, and C 3-activator in the human liver as PAS-negative globular hyaline bodies.
    Storch W; Riedel H; Trautmann B; Justus J; Hiemann D
    Exp Pathol; 1982; 21(3):199-203. PubMed ID: 6288441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergy between two active sites of human complement receptor type 1 (CD35) in complement regulation: implications for the structure of the classical pathway C3 convertase and generation of more potent inhibitors.
    Krych-Goldberg M; Hauhart RE; Porzukowiak T; Atkinson JP
    J Immunol; 2005 Oct; 175(7):4528-35. PubMed ID: 16177096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protection of baculovirus-vectors against complement-mediated inactivation by recombinant soluble complement receptor type 1.
    Hofmann C; Hüser A; Lehnert W; Strauss M
    Biol Chem; 1999 Mar; 380(3):393-5. PubMed ID: 10223343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complement activation in nonsystemic glomerular diseases in children.
    Levy M; Habib R
    Paediatrician; 1981; 10(5-6):314-42. PubMed ID: 7036045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structural insights into the central complement component C3.
    Janssen BJ; Gros P
    Mol Immunol; 2007 Jan; 44(1-3):3-10. PubMed ID: 16875735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.